RenovoRx

02/06/2026

Join us on Saturday, February 7th, 1:45–2:00 PM ET, at SIO 2026 for an engaging presentation by expert interventional oncologists, Dr. Paula Novelli, UPMC, and Dr. Khashayar Farsad, OHSU. They will share their real-world insights and potential benefits on the use of the TAMP™ therapy platform for oncology management. https://bit.ly/46l7RB2

02/05/2026

Christopher Laing, MD of Sutter Health comments on the clinical data supporting the TAMP™ therapy platform which will be presented at the SIO 2026 tomorrow, February 6th. For more info, visit: https://bit.ly/3ZcZYJj

02/05/2026

We’re pleased to welcome Mark Voll as RenovoRx’s Chief Financial Officer, effective February 1, 2026. He joins our leadership team during an important chapter of RenovoRx’s commercial growth. Learn more: https://bit.ly/49YDeCX

02/05/2026

On , RenovoRx joins the global community in raising awareness about the urgent need for innovative treatment options for patients diagnosed with difficult-to-treat cancers.

At RenovoRx, we are committed to transforming the lives of patients with cancer through targeted chemotherapeutic delivery via the TAMP™ therapy platform.

Together, we continue the fight against cancer. www.worldcancerday.org

02/04/2026

We are excited that clinical data supporting TAMP’s novel approach to targeted, pressure-mediated chemotherapeutic delivery and reinforcing its potential to provide individualized, optimized drug-delivery, will be presented at the SIO 2026 this Friday, February 6th at 5:45-6:00 PM ET. For details: https://bit.ly/3ZcZYJj

02/03/2026

Attending 2026 SIO Annual Scientific Meeting this week? A clinical data abstract will be presented providing supportive evidence for RenovoRx’s TAMP™ therapy platform’s novel approach to targeted, pressure-mediated drug-delivery. Visit us at Booth #419 to learn more. https://bit.ly/3Z4Ois0

02/03/2026

Listen to The Leading Difference podcast to hear our CEO, Shaun Bagai, discuss his definition of effective leadership, emphasizing continuous learning, growth, and purpose-driven decision-making. For more: https://bit.ly/3ZzZ0GZ

01/29/2026

Our CEO, Shaun Bagai, spoke with Genetic Engineering & Biotechnology News about RenovoRx's novel drug delivery Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and the ongoing Phase III TIGeR‑PaC clinical trial in . Read the article here: https://bit.ly/49Oadsp

01/28/2026

The RenovoRx team is excited that a clinical data abstract supporting the TAMP™ therapy platform has been accepted at the upcoming 2026 SIO Annual Scientific Meeting. The abstract provides supportive evidence for TAMP’s novel approach to targeted, pressure-mediated drug-delivery. The meeting will be held February 4–8, 2026 in Savannah, Georgia. For details: https://bit.ly/3Z4Ois0

01/27/2026

RenovoRx CEO Shaun Bagai talks leadership, career lessons, and MedTech insights on The Leading Difference podcast. Now available on all major podcast platforms. Listen to the full episode here: https://bit.ly/3ZzZ0GZ

01/22/2026

Genetic Engineering & Biotechnology News, a leading biotech publication, recently featured an interview with Shaun Bagai, CEO of RenovoRx, highlighting the company’s novel Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. The article explores TAMP’s potential to minimize toxicities associated with systemic chemotherapy and to improve patient outcomes. Read more: https://bit.ly/49Oadsp

Emerging technologies bring the fight directly to the cancer cells.

01/21/2026

Excited to share that RenovoRx is seeing continued commercial growth, with leading U.S. cancer centers adopting the FDA-cleared RenovoCath® as a standalone device in their oncology programs. For more: https://bit.ly/4a433kT